ACTIVELY ENROLLING STUDIES
A011401- (opened 10/2016): Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWELL).
A011502 - (opened 10/2016): A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive HER2 Negative Breast Cancer: the ABC Trial.
A2011601 - (opened 2/2019): Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502. (ABC Companinon Study)
S1703 - (opened 4/2019): Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
A021703 SOLARIS - (opened 11/2019): Randomized double-blind phase III trial of vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer.
HEAD AND NECK
EA3161 - A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA.
ALCHEMIST Trials - (opened 8/2016):
- A151216 (ALCHEMIST-Screen) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial.
- A081105 (ALCHEMIST-EGFR) Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC.
- E5412 (ALCHEMIST-ALK) Phase III Double-blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.
EA5181 - Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
NRG-LU005 - (opened 9/2019): Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.
DB102-02 ENGINE - (opened 5/2019): A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™.
Connect MDS/AML - (opened 6/2013): The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.
EA8143 PROSPER - (opened 8/2017): A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy.
AMULET AMPLATAZER: Amulet LAA Occluder Randomized Conrol Trial
APPRAISE: Assessment of Primary Prevention Patients Receiving An ICD – Systematic Evaluation of ATP
ASAP-TOO: Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation
COVID- PACT: A Multicenter, Randomized- Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complication in Critically-Ill COVID-19 Patients
For More Information:
If you would like additional information about the Center for Research, please send your name, company or practice name, address and telephone number to the following address:
Watson Clinic Center for Research
1600 Lakeland Hills Blvd
Lakeland, FL 33805
Attn: Noreen McGowan, BSN, CCRC, Director
Phone 863-688-6826 · FAX 863-688-5842
Please indicate which of the following type(s) of information you would like:
- Additional information about current protocols
- Center for Research grants
- Contributing to Center for Research funding
- Involvement in Center for Research protocols
Return to Clinical Trials Page